Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06733441 · ClinicalTrials.gov registry record · Phase 1
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
A Phase 1 study of Lymphoma, sponsored by Treeline Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT06733441 is a Phase 1 study of Lymphoma that is actively recruiting participants, run by Treeline Biosciences. The registered enrollment target is 50 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT06733441, a Phase 1 study of Lymphoma, is actively recruiting participants, sponsored by Treeline Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Conditions Studied
Interventions
- DRUG TLN-254
Study Locations (5)
California
- Stanford Cancer Institute - Stanford
Missouri
- Washington University School of Medicine - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Tennessee
- Sarah Cannon Research Institute - Nashville
British Columbia
- British Columbia Cancer Agency - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-12-16 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06733441
The ClinicalTrials.gov registry entry for NCT06733441 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (90% lower). The listed sponsor is Treeline Biosciences, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which TLN-254 is the first listed.
NCT06733441 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT06733441 about?
NCT06733441 is a clinical study titled "A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma". The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
What is the current status of trial NCT06733441?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-12-16. Estimated completion is 2028-11-15.
What conditions does trial NCT06733441 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT06733441?
The interventions under investigation include: TLN-254 (DRUG).
Who is sponsoring clinical trial NCT06733441?
This trial is sponsored by Treeline Biosciences, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06733441 being conducted?
This trial has 5 study locations across California, Missouri, New York, Tennessee, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies.
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.